A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multiple-Dose Study to Assess the Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

Trial Profile

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multiple-Dose Study to Assess the Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Apr 2018

At a glance

  • Drugs NYX 2925 (Primary)
  • Indications Neuropathic pain
  • Focus Therapeutic Use
  • Sponsors Aptinyx
  • Most Recent Events

    • 02 Apr 2018 Planned End Date changed from 30 Sep 2018 to 30 Oct 2018.
    • 02 Apr 2018 Planned primary completion date changed from 30 Aug 2018 to 30 Oct 2018.
    • 01 Aug 2017 According to an Aptinyx media release, first patient has been randomized.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top